Abstract：【Objective】 To investigate the value of mammography and magnetic resonance imaging (MRI) combined with serum procalcitonin (PCT) in the differential diagnosis of benign and malignant breast tumors. 【Methods】 A total of 120 female patients with breast masses treated in the Yulin First Hospital were selected as the research object. According to the results of pathological examination, the patients were divided into benign breast tumor group (n=54) and malignant breast tumor group (n=66). All patients underwent mammography and MRI. At the same time, the level of serum PCT was detected by enzyme-linked immunosorbent assay (ELISA). The consistency between mammography, MRI, serum PCT and their combination in detecting breast malignant tumors and clinicopathological diagnosis was analyzed. The diagnostic value of mammography, MRI, serum PCT and their combination in breast malignant tumors was analyzed and compared. 【Results】 The level of serum PCT in breast malignant tumor group was significantly higher than that in breast benign tumor group (P<0.05). There were 54, 58 and 49 cases of breast malignant tumors detected by X-ray photography, MRI and serum PCT, respectively. The consistency with clinicopathological diagnosis was high, high and moderate respectively (Kappa=0.604, 0.734 and 0.493, all P<0.05). A total of 63 patients with breast cancer were detected by the combination of the three, which was in excellent agreement with the clinicopathological diagnosis ( Kappa=0.883, P<0.05). The sensitivity and accuracy of X-ray photography and serum PCT were lower than the combined detection, and the missed diagnosis rate was higher than the combined detection (P<0.05). 【Conclusion】 X-ray photography, MRI and serum PCT have certain diagnostic value for benign and malignant breast tumors. The detection rate of MRI is higher, and the combined diagnostic value of the three is higher than that of the three alone.
马小伟, 李耀锋. 乳腺X线摄影、MRI联合血清PCT在诊断乳腺良恶性肿瘤中的应用价值[J]. 医学临床研究, 2022, 39(5): 732-735.
MA Xiao-wei, LI Yao-feng. Application Value of Mammography, MRI and Serum PCT in the Diagnosis of Benign and Malignant Breast Tumors. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 732-735.
[1] VONDELING G T, MENEZES G L, DVORTSIN E P, et al.Burden of early, advanced and metastatic breast cancer in the Netherlands[J].BMC Cancer,2018, 18(1):262-275.
[2] 路东晓, 王匡君, 张周龙. 超声, 乳腺X线摄影, 磁共振成像检查诊断乳腺肿块性质的价值与卫生经济学评价[J].肿瘤基础与临床, 2020, 33(4):346-348.
[3] PIERPAOLO P, ANDREA N, GIORGI R P, et al. Digital mammography versus digital mammography plus tomosynthesis for breast cancer screening: the reggio emilia tomosynthesis randomized trial[J].Radiology,2018, 288(2):375-385.
[4] PATEL B K, HILAL T, COVINGTON M, et al. Contrast-enhanced spectral mammography is comparable to mri in the assessment of residual breast cancer following neoadjuvant systemic therapy[J].Ann Surg Oncol,2018, 25(5):1350-1356.
[5] 朱丽, 黎莉. 乳腺癌患者血清糖类抗原153、癌胚抗原、铁蛋白及降钙素水平变化的价值[J].中国老年学杂志, 2019, 39(5):1069-1071.
[6] 李萍, 周云, 黄岩. X线摄影超声及核磁共振检查对乳腺良恶性病变的诊断价值比较[J].河北医学, 2016, 22(11):1821.
[7] 李继斌,赵明增,张录林,等.乳腺癌患者MRI影像学征象与病理特征的相关性[J].医学临床研究,2021,38(10):1585-1587.
[8] 何辉, 宋慧浩, 郭聪. 超声造影联合弹性成像检查诊断乳腺良恶性病变的价值分析[J].解放军预防医学杂志, 2019, 37(4):198.
[9] COHEN E O, WEAVER O O, TSO H H, et al. Breast cancer screening via digital mammography, synthetic mammography, and tomosynthesis[J].Am J Prev Med,2020, 58(3):470-472.
[10] 张晓晶, 王习, 娄昕, 等. 联合DWI和DCE-MRI评估乳腺癌新辅助化疗的应用价值[J].医学影像学杂志, 2018, 28(5):758-761.
[11] 林蓉蓉, 陈晓燕, 黄洪磊, 等. 超声和X线摄影及MRI多定量参数对触诊阴性乳腺癌诊断分析[J].医学影像学杂志, 2020, 30(5):167-170.
[12] WANG J J, WANG Y L, GE X X, et al. Prognostic values of platelet-associated indicators in resectable lung cancers[J].Technol Cancer Res Treat,2019, 18(1):1-13.
[13] 王军梅, 朱李茹. 乳腺癌患者血清糖类抗原15-3、癌胚抗原、铁蛋白、降钙素水平的变化及临床意义[J].中国卫生检验杂志, 2018, 28(13):1605-1607.
2022, Vol. 39 
